Last reviewed · How we verify
Bolus dose of Cefazolin
Cefazolin inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins and blocking cross-linking of peptidoglycan.
Cefazolin inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins and blocking cross-linking of peptidoglycan. Used for Surgical site infection prophylaxis, Bacterial infections caused by susceptible organisms (skin, soft tissue, respiratory, urinary tract, biliary, bone, and joint infections).
At a glance
| Generic name | Bolus dose of Cefazolin |
|---|---|
| Also known as | Standard mode of prophylactic cefazolin administration |
| Sponsor | University of Florida |
| Drug class | First-generation cephalosporin |
| Target | Penicillin-binding proteins (PBPs) |
| Modality | Small molecule |
| Therapeutic area | Infectious Disease |
| Phase | FDA-approved |
Mechanism of action
Cefazolin is a first-generation cephalosporin antibiotic that works by disrupting the formation of the bacterial cell wall. It binds to penicillin-binding proteins and prevents the cross-linking of peptidoglycan strands, which are essential for cell wall integrity. This leads to cell wall instability and bacterial cell death, making it bactericidal against susceptible gram-positive and some gram-negative organisms.
Approved indications
- Surgical site infection prophylaxis
- Bacterial infections caused by susceptible organisms (skin, soft tissue, respiratory, urinary tract, biliary, bone, and joint infections)
Common side effects
- Hypersensitivity reactions (rash, urticaria)
- Phlebitis at injection site
- Diarrhea
- Nausea/vomiting
- Anaphylaxis
Key clinical trials
- Opioid-Free vs Opioid-Based Anesthesia in Bariatric Surgery (NA)
- Target Attainment of Continuous Infusion Flucloxacillin and Cefazolin Coupled With TDM vs. Standard of Care Treatment in Patients With Complicated S. Aureus Infection (PHASE2)
- Skeletal Muscle and Adipose Tissue Study (PHASE4)
- Probability of Target Attainment With Standard Intermittent Bolus Administration of Cefazolin in Patients With Complicated Infections Caused by Staphylococcus Aureus
- Continuous v Bolus Infusion of Cefazolin During Ventral Hernia Repair (PHASE4)
- Preoperative Antibiotic Dosing for Total Knee Arthroplasty (PHASE4)
- Pharmacokinetics of Bolus Versus Continuous Cefazolin Infusion in Patients Undergoing Major Surgery (NA)
- Core Temperature Variations During Midazolam vs Propofol Sedation for Neuraxial Anesthesia (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |